Zurück
old.nasdaq.com/de/symbol/kzr/real-time
Top-News
KZR 18,33$
Beiträge:
123
Zugriffe: 44.918 / Heute: 6
Zugriffe: 44.918 / Heute: 6
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi IBEX 35 Doble Apalancado Diario (2x) UCITS ETF Acc
Perf. 12M: +103,50%
Amundi MSCI Greece UCITS ETF Dist
Perf. 12M: +52,19%
Amundi IBEX 35 UCITS ETF Acc
Perf. 12M: +47,37%
Amundi IBEX 35 UCITS ETF Dist
Perf. 12M: +45,06%
old.nasdaq.com/de/symbol/kzr/real-time
Mein aktueller Liebling im Depot! Auch bei dem Kursgemetzel noch grün. Hoffe das bleibt so!
verkauf hier gar nichts. Vom Tief schon wieder 50 Cent entfernt.
old.nasdaq.com/de/symbol/kzr/real-time
old.nasdaq.com/de/symbol/kzr/real-time
Wird unter Cash gehandelt, aber in Zeiten von Corona muss man sich immer noch einen Pfeil im Köcher lassen, daher warte ich noch auf günstigere Kurse.
old.nasdaq.com/de/symbol/kzr/real-time
ein paar Stücke und es geht 2stellig rauf oder runter
old.nasdaq.com/de/symbol/kzr/real-time
old.nasdaq.com/de/symbol/kzr/real-time
anders gesagt, wir bauen aktuell an einer Unterstützung bei 4 USD.
Noch kein Stück verkauft. Im Gegenteil, mal sehen ob die 5,50 USD bald mal geknackt werden...
www.analystratings.com/articles/...r-kezar-life-sciences-kzr/
old.nasdaq.com/de/symbol/kzr/real-time
We currently estimate that our cash, cash equivalents and marketable securities as of March 31, 2020 will be sufficient to fund our operations into the thirdquarter of 2022. (Seite 18)
investors.kezarlifesciences.com/...d28b-4897-8a91-2c86f1aa4ee2
Sind sowieso ein paar schöne Passagen dabei:
Additionally, we are advancing our novel research platform targeting the Sec61 translocon and the protein secretion pathway to discover and develop smallmolecule therapeutics targeting oncology indications. Our first clinical candidate in this program, KZR-261, has demonstrated broad anti-tumor activity inpreclinical models of both solid and hematologic malignancies. KZR-261 is undergoing laboratory studies and manufacturing activities in support of aninvestigational new drug, or IND, application, which we anticipate submitting to the U.S. Food and Drug Administration, or FDA, in the first quarter of2021 for a Phase 1 clinical trial in solid tumors. We believe this discovery platform has the potential to yield oral small molecule candidates that, ifsuccessfully developed and approved, could serve as alternatives to currently marketed biologic therapeutics to act as cytotoxic anti-cancer agents or toblock the secretion of novel targets of interest in immuno-oncology or inflammation.
investors.kezarlifesciences.com/...d28b-4897-8a91-2c86f1aa4ee2
Sind sowieso ein paar schöne Passagen dabei:
Additionally, we are advancing our novel research platform targeting the Sec61 translocon and the protein secretion pathway to discover and develop smallmolecule therapeutics targeting oncology indications. Our first clinical candidate in this program, KZR-261, has demonstrated broad anti-tumor activity inpreclinical models of both solid and hematologic malignancies. KZR-261 is undergoing laboratory studies and manufacturing activities in support of aninvestigational new drug, or IND, application, which we anticipate submitting to the U.S. Food and Drug Administration, or FDA, in the first quarter of2021 for a Phase 1 clinical trial in solid tumors. We believe this discovery platform has the potential to yield oral small molecule candidates that, ifsuccessfully developed and approved, could serve as alternatives to currently marketed biologic therapeutics to act as cytotoxic anti-cancer agents or toblock the secretion of novel targets of interest in immuno-oncology or inflammation.
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Kezar Life Sciences Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 122 | KZR 18,33$ | Vassago | Highländer49 | 17.10.25 13:14 | |
| 4 | KZR 3,86$ (neues 52 WT) | Vassago | Vassago | 26.03.21 10:12 |